Dnca Finance Decreases Position in Stryker Corporation $SYK

Dnca Finance reduced its stake in Stryker Corporation (NYSE:SYK) by 23.9% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 15,720 shares of the medical technology company’s stock after selling 4,930 shares during the period. Dnca Finance’s holdings in Stryker were worth $5,811,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Clayton Financial Group LLC purchased a new stake in shares of Stryker during the 3rd quarter worth approximately $26,000. United Financial Planning Group LLC purchased a new position in shares of Stryker in the 3rd quarter valued at $27,000. Elevation Point Wealth Partners LLC acquired a new stake in Stryker during the 2nd quarter worth $28,000. Kilter Group LLC purchased a new stake in Stryker in the second quarter valued at $29,000. Finally, Howard Hughes Medical Institute purchased a new stake in Stryker in the second quarter valued at $29,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Key Stories Impacting Stryker

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Citi and some analysts view the pullback as a potential buying opportunity given Stryker’s fundamentals and upcoming catalysts — Citi put together a “90‑day catalyst watch” that sees upside despite the outage. Citi Sees Upside
• Positive Sentiment: Technicals may offer support: commentators note shares became oversold after the sell‑off and found support at a prior level, suggesting a possible technical bounce for traders. Stock Of The Day: Where Is The Bottom For Stryker?
• Neutral Sentiment: Stryker has publicly confirmed a cybersecurity incident and is investigating; the company is communicating updates as the situation evolves. Company Announcement
• Neutral Sentiment: Reporting shows the attack is causing real operational disruption to order processing, manufacturing and shipments — facts investors must watch to judge duration and revenue impact. Reuters: Disruption Report
• Negative Sentiment: Hackers claiming Iran linkage (group “Handala”) say the attack included destructive “wiper” activity and exfiltration of large volumes of data — allegations that raise the risk of extended downtime and regulatory/PR fallout. IBTimes: Hacker Claim
• Negative Sentiment: Operational paralysis from the incident has already pressured the stock, with multiple outlets reporting multi‑percent intraday declines as orders and shipments stall. Yahoo: Shares Fall
• Negative Sentiment: Social‑media driven selling amplified volatility — a viral Reddit thread and related headlines accelerated the recent drop, adding short‑term downside risk beyond fundamentals. 24/7 Wall St.: Reddit Impact

Insider Buying and Selling at Stryker

In other Stryker news, Director Ronda E. Stryker sold 250,000 shares of Stryker stock in a transaction that occurred on Wednesday, February 4th. The stock was sold at an average price of $362.92, for a total value of $90,730,000.00. Following the transaction, the director directly owned 2,457,331 shares in the company, valued at approximately $891,814,566.52. This trade represents a 9.23% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 5.90% of the company’s stock.

Stryker Trading Down 0.1%

NYSE SYK opened at $336.95 on Friday. The firm’s fifty day moving average is $365.20 and its two-hundred day moving average is $367.71. Stryker Corporation has a one year low of $328.23 and a one year high of $404.87. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.21 and a current ratio of 1.89. The firm has a market cap of $128.95 billion, a PE ratio of 40.11, a P/E/G ratio of 1.97 and a beta of 0.85.

Stryker (NYSE:SYK) last announced its earnings results on Thursday, January 29th. The medical technology company reported $4.47 earnings per share for the quarter, topping the consensus estimate of $4.40 by $0.07. Stryker had a net margin of 12.92% and a return on equity of 24.41%. The business had revenue of $7.17 billion during the quarter, compared to the consensus estimate of $7.12 billion. During the same quarter in the prior year, the firm earned $4.01 earnings per share. The business’s quarterly revenue was up 11.4% compared to the same quarter last year. Analysts expect that Stryker Corporation will post 13.47 earnings per share for the current year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, April 30th. Shareholders of record on Tuesday, March 31st will be given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 1.0%. The ex-dividend date of this dividend is Tuesday, March 31st. Stryker’s dividend payout ratio (DPR) is presently 41.90%.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on SYK shares. William Blair reaffirmed an “outperform” rating on shares of Stryker in a report on Thursday, March 5th. Robert W. Baird set a $437.00 target price on Stryker in a report on Friday, January 30th. Sanford C. Bernstein raised their price target on Stryker from $450.00 to $465.00 and gave the stock an “outperform” rating in a research note on Friday, January 9th. Jefferies Financial Group reaffirmed a “buy” rating and set a $465.00 price target on shares of Stryker in a research report on Wednesday, March 4th. Finally, Citizens Jmp upgraded Stryker from a “market perform” rating to an “outperform” rating and set a $440.00 price objective for the company in a research note on Friday, December 19th. Fourteen equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $428.61.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.